"Pillar Biosciences...announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Premarket Approval (PMA) supplement application for its Pan-cancer oncoReveal™ CDx. The supplement, if approved, will expand the label/indication of Pillar Bioscience’s oncoReveal™ Dx Lung & Colon Cancer Assay to include actionable targets for eight additional cancer types, bringing the total detectable cancers to ten."